HISTAMINE
MOLECULAR TARGETHistamine H2 receptor (human)
HISTAMINE (Histamine H2 receptor (human)) is targeted by 26 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting HISTAMINE
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Cimetidine | 1.79 | 5 |
| 2 | Mianserin | 1.61 | 4 |
| 3 | Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent | 1.61 | 4 |
| 4 | Astemizole Antihistamine drug now withdrawn from | 1.61 | 4 |
| 5 | Cyproheptadine | 1.61 | 4 |
| 6 | Lisuride | 1.61 | 4 |
| 7 | Maprotiline | 1.61 | 4 |
| 8 | Metergoline | 1.61 | 4 |
| 9 | Nortriptyline | 1.61 | 4 |
| 10 | Promethazine | 1.61 | 4 |
| 11 | Clotrimazole | 1.39 | 3 |
| 12 | Quetiapine Fumarate | 1.10 | 2 |
| 13 | Amoxapine | 1.10 | 2 |
| 14 | Cinnarizine | 1.10 | 2 |
| 15 | Cyclizine | 1.10 | 2 |
| 16 | Dimenhydrinate | 1.10 | 2 |
| 17 | Domperidone | 1.10 | 2 |
| 18 | Econazole | 1.10 | 2 |
| 19 | Famotidine | 1.10 | 2 |
| 20 | Flunarizine Flunarizine is | 1.10 | 2 |
| 21 | Loratadine | 1.10 | 2 |
| 22 | Miconazole | 1.10 | 2 |
| 23 | Trazodone | 1.10 | 2 |
| 24 | Histamine | 0.69 | 1 |
| 25 | Metiamide | 0.69 | 1 |
| 26 | Ranitidine | 0.69 | 1 |
About HISTAMINE as a Drug Target
HISTAMINE (Histamine H2 receptor (human)) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 26 compounds with documented HISTAMINE interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
HISTAMINE inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.